GlassScriptPhysician profile
Sarah J Gomez
NPI 1003425604
$5,967.93
in general payments reported to CMS, 2019-2025
38 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $541 · 2023: $1,317 · 2024: $1,929 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,982.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,902.96 | 2021-2025 | |
| Amgen INC. | $378.95 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $368.09 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $332.07 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lundbeck LLC | $262.27 | 2022-2025 | Vyepti, Rexulti |
| Novo Nordisk INC | $257.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $256.99 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $215.39 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.81 | 2021-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $177.60 | 2024-2025 | Fanapt, Hetlioz |
| Cvrx, INC. | $159.13 | 2024 | Barostim Neo System |
| Pfizer INC. | $157.19 | 2023-2025 | |
| Boston Scientific Corporation | $150.37 | 2023 | Watchman Access System, Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.27 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $114.61 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.